The U.S. biotech company said adjusted profit rose to $1.67 per share, ahead of analyst expectations of $1.50, according to Refinitiv data, and up from 69 cents per share a year earlier, when it took $1.85 billion in charges mostly for a legal settlement. Quarterly revenue rose 2% to $7.4 billion, topping  analysts' estimates of $6.64 billion.It forecast 2023 sales of $26 billion to $26.5 billion, ahead of analyst expectations of $25.8 billion, and adjusted earnings of $6.60 to $7 per share. The midpoint of the earnings forecast is also above analysts' estimates for $6.73 per share.Sales of COVID-19 treatment remdesivir, sold under the brand name Veklury, were $1 billion, far beyond the $511 million analysts had expected even as they slowed 26% from the previous year. While Veklury sales declined by about half in the United States and Europe as COVID hospitalization rates fell, theyÂ tripled  in other international markets.Gilead's HIV sales increased 5% to $4.8 billion in the quarter, with Biktarvy rising 15% to $2.9 billion versus the $2.8 billion analysts expected.Descovy sales rose 13% to $537 million, outstripping the analysts' forecast of $495 million.Gilead's cancer franchise also saw sales increase by 71% to $419 million. Yescarta, a CAR-T lymphoma treatment, booked $337 million, while leukemia and lymphoma treatment Tecartus came in at $82 million. (Reporting by Sriparna Roy in Bengaluru, Caroline Humer and Michael Erman in New York; Editing by Bill Berkrot)By Michael Erman and Sriparna  Roy